Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target

Clinical Cancer Research

Volumn 16, Issue 18, 2010, Pages 4527-4531

  Plummer, Ruth ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; 2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; 8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; BSI 201; CARMUSTINE; CEP 9722; CP 466722; E 7016; GPI 21016; INIPARIB; LOMEGUATRIB; LT 673; METHOXYAMINE; MK 4827; MP 470; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NU 7441; OLAPARIB; PEMETREXED; PF 0367338; SAR 240550; TEMOZOLOMIDE; TRC 102; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DNA DAMAGE; DNA REPAIR; DRUG RESEARCH; PRIORITY JOURNAL; REVIEW; TUMOR RESISTANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA DAMAGE; DNA REPAIR ENZYMES; DRUG DISCOVERY; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION;

EID: 77956693456     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0984     Document Type: Review

References (41)

1. Hoeijmakers JH. Genone maintenance mechanisms for preventing cancer. Nature 2001;411:366-74.
2. Bernstein C, Bernstein H, Payne CM, Garewal H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res 2002;511:145-78. (Pubitemid 34621252)
3. Christmann M, Tomicic MT, Roos WP, Kaina B. Mechanisms of human DNA repair: an update. Toxicology 2003;193:3-34. (Pubitemid 37340141)
4. Heinen CD, Schmutte C, Fishel R. DNA repair and tumorigenesis: lessons from hereditary cancer syndromes. Cancer Biol Ther 2002;1:477-85.
5. Risinger MA, Groden J. Crosslinks and crosstalk: human cancer syndromes and DNA repair defects. Cancer Cell 2004;6:539-45. (Pubitemid 40017697)
6. de la Chapelle A. Genetic predisposition to colorectal cancer. Nat Rev Cancer 2004;4:769-80.
7. Staibano S, Pepe S, Lo Muzio L, et al. Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. Hum Pathol 2005;36:724-31.
8. Wharton SB, McNelis U, Bell HS, Whittle IR. Expression of poly(ADP-ribose) polymerase and distribution of poly(ADP-ribosyl)ation in glioblastoma and in a glioma multicellular tumour spheroid model. Neuropathol Appl Neurobiol 2000;26:528-35. (Pubitemid 32049852)
9. Hansen WK, Kelly M. Review of mammalian DNA repair and translational implications. J Pharmacol Exp Ther 2000;295:1-9.
10. 6-methylguanine. Mutagenesis 2002;17:483-7.
11. Fink D, Aebi S, Howell S. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998;4:1-6. (Pubitemid 28062870)
12. Soejima H, Zhao W, Mukai T. Epigenetic silencing of the MGMT gene in cancer. Biochem Cell Biol 2005;83:429-37. (Pubitemid 41626761)
13. Park Y, Gerson SL. DNA repair defects in stem cell function and aging. Annu Rev Med 2005;56:495-508. (Pubitemid 40299795)
14. Schilsky RL, Dolan ME, Bertucci D, et al. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res 2000;6:3025-31. (Pubitemid 30637724)
15. Quinn JA, Pluda J, Dolan ME, et al. Phase II trial of carmustine plus O (6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 2002;20:2277-83.
16. Gajewski TF, Sosman J, Gerson SL, et al. Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. Clin Cancer Res 2005;11:7861-5. (Pubitemid 41611631)
17. Ranson M, Middleton MR, Bridgewater J, et al. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2006;12:1577-84.
18. Ranson M, Hersey P, Thompson D, et al. A randomised trial of the combination of lomeguatrib and temozolomide alone in patients with advanced melanoma. J Clin Oncol 2007;25:2540-5.
19. Plummer R, Jones C, Middleton M, et al. Phase I study of the poly (ADP-Ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008;14:7917-23.
20. Plummer R, Lorigan P, Evans J, et al. First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). J Clin Oncol 2006;24:8013.
21. Rajan A, Carter CA, Gutierrez M, et al. A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin plus gemcitabine in adults with solid tumors. J Thorac Oncol 2009;4:S598-9.
22. Rajan A, Gutierrez M, Kummar S, et al. A phase I combination study of Azd2281 and cisplatin plus gemcitabine in adults with solid tumors. Ann Oncol 2009;20:42-3.
23. Kummar S, Ji J, Zhang Y, et al. A phase I combination study of Abt-888 and topotecan hydrochloride in adults with refractory solid tumors and lymphomas. Ann Oncol 2009;20:42.
24. O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol 2009;27:3.
25. BiPar Sciences presents interim phase 2 results for PARP inhibitor BSI-201 at San Antonio Breast Cancer Symposium. Cancer Biol Ther 2009;8:2-3.
26. Audeh M, Penson R, Friedlander M, et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J Clin Oncol 2009;27:5500.
27. Tutt A, Robson M, Garber J, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 2009;27:CRA501.
28. Fong P, Boss D, Yap T, et al. Inhibition of poly(ADP-Ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
29. Griffin RJ, Fontana G, Golding BT, et al. Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro. J Med Chem 2005;48:569-85.
30. Hickson I, Zhao Y, Richardson CJ, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004;64:9152-9.
31. Huang G, Wang H, Yang LX, et al. Enhancement of radiation-induced DNA damage and inhibition of its repair by a novel camptothecin analog. Anticancer Res 2009;30:937-44.
32. Ismail IH, Martensson S, Moshinsky D, et al. SU11752 inhibits the DNA-dependent protein kinase and DNA double-strand break repair resulting in ionizing radiation sensitization. Oncogene 2004;23:873-82. (Pubitemid 38250932)
33. Hollick JJ, Rigoreau LJ, Cano-Soumillac C, et al. Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase. J Med Chem 2007;50:1958-72.
34. Calabrese CR, Almassy R, Barton S, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004;96:56-67.
35. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-7.
36. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
37. Ashwell S, Janetka JW, Zabludoff S. Keeping checkpoint kinases in line: new selective inhibitors in clinical trials. Expert Opin Investig Drugs 2008;17:1331-40.
38. Janetka JW, Ashwell S. Checkpoint kinase inhibitors: a review of the patent literature. Expert Opin Ther Pat 2009;19:165-97.
39. Kuntz K, O'Connell MJ. The G(2) DNA damage checkpoint: could this ancient regulator be the Achilles heel of cancer? Cancer Biol Ther 2009;8:1433-9.
40. Kennedy RD, D'Andrea AD. DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J Clin Oncol 2006;24:3799-808.
41. Kennedy RD, Chen CC, Stuckert P, et al. Fanconi anemia pathway-deficient tumour cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest 2007;117:1440-9. (Pubitemid 46718432)